Vilobelimab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Vilobelimab Usage And Synthesis

Uses

Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc[1].

References

[1] Michael Bauer, et al. Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study). Crit Care Explor. 2021 Nov 17;3(11):e0577. DOI:10.1097/CCE.0000000000000577

Vilobelimab(2250440-41-4)Related Product Information

• Vesencumab
• Ginisortamab
• Recaticimab
• Morolimumab
• Sotevtamab
• Etigilimab
• Ascrinvacumab
• Romlusevimab
• Keliximab
• Duvortuxizumab